Equities
Health CareMedical Equipment and Services
  • Price (EUR)31.52
  • Today's Change-0.48 / -1.50%
  • Shares traded122.52k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of May 17 2024 16:35 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SCHOTT Pharma AG & Co. KGaA is a Germany-based Company, which designs advanced drug containment and drug delivery solutions for the pharmaceutical and biotech industries. The Company's product portfolio ranges from drug containment solutions to drug delivery systems manufactured in collaboration with industry partners. Its selection of pharmaceutical syringes, cartridges, vials, and ampoules is one of the widest and advanced on the market for injectable drugs.

  • Revenue in EUR (TTM)905.64m
  • Net income in EUR158.11m
  • Incorporated2022
  • Employees4.65k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Medacta Group SA510.57m47.34m2.48bn1.73k52.457.5023.494.872.332.3325.1516.300.79790.87085.92290,631.307.407.899.0910.5768.1070.439.2710.090.90044.800.381717.0116.8513.382.410.69378.32--
Elekta AB (publ)1.56bn123.07m2.62bn4.58k22.113.0912.041.673.743.7447.6026.820.62083.292.904,150,570.004.894.328.697.8937.9039.937.887.680.82194.020.410665.7915.957.83-18.28-6.9012.8611.38
Ambu A/S680.23m49.19m4.15bn4.75k95.306.2542.096.101.381.3819.0921.050.72512.137.171,099,437.005.243.815.994.6257.9159.377.235.431.4916.930.10122.897.4512.8880.65-13.006.67--
Getinge AB2.77bn196.15m4.15bn11.86k22.671.6012.201.508.398.39118.22118.800.60012.536.792,742,908.004.295.315.566.9845.3747.837.158.690.756911.470.203537.8712.495.66-3.17---0.394434.49
GN Store Nord A/S2.44bn71.84m4.33bn7.05k57.963.1314.251.783.703.70127.0468.440.61393.004.732,541,382.001.944.913.227.4450.5053.293.166.820.41182.500.558236.84-3.0311.30-55.38-28.747.53--
Ypsomed Holding AG516.47m73.54m4.62bn2.20k62.787.9330.458.955.315.3137.3142.030.58884.925.75247,016.008.384.4412.706.7732.0426.9514.246.870.557730.610.261418.547.021.31121.92-0.303420.32-1.47
SCHOTT Pharma AG & Co KgaA905.64m158.11m4.82bn4.65k30.486.7023.285.321.051.056.014.78------194,928.30--------35.23--17.48--1.08--0.094--9.43--21.11------
ConvaTec Group PLC1.97bn119.94m6.11bn10.13k51.043.9219.243.100.05010.05010.82410.6520.58652.576.14166,992.603.572.364.182.7356.0455.036.084.340.88352.650.4367127.293.373.18107.15-6.9312.3731.41
Data as of May 17 2024. Currency figures normalised to SCHOTT Pharma AG & Co KgaA's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.